Citrate: How to get started and what, when, and how to monitor?

被引：11

作者：

Honore, Patrick M. ^{[1
]}

De Bels, David ^{[1
]}

Preseau, Thierry ^{[2
]}

Redant, Sebastien ^{[1
]}

Spapen, Herbert D. ^{[3
]}

机构：

[1] CHU Brugmann, ICU Dept, Pl Van Gehuchtenpl 4, B-1020 Brussels, Belgium

[2] CHU Brugmann, Emergency Dept, Brussels, Belgium

[3] VUB Univ, Univ Ziekenhuis Brussel, Brussels, Belgium

来源：

JOURNAL OF TRANSLATIONAL INTERNAL MEDICINE | 2018年 / 6卷 / 03期

关键词：

regional citrate anticoagulation; diluted citrate; monitoring; metabolic complications; CONTINUOUS VENOVENOUS HEMOFILTRATION; CONTINUOUS RENAL REPLACEMENT; REGIONAL CITRATE; ANTICOAGULATION; HEMODIAFILTRATION; HEMODIALYSIS; HEPARIN;

D O I：

10.2478/jtim-2018-0026

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In most of the case, regional citrate anticoagulation is using diluted citrate around 1% depending on the types used in clinical practice. Diluted citrate is much more safer when compared to highly concentrated citrate around 4% or even more. In clinical practice, trisodium citrate is used in high concentration (around 30%) as a bactericidal agent with anticoagulant properties for locking deep venous catheters used in hemodialysis (HD; close to 25-30% of citrate). In this review article, buffer and anticoagulant potential of citrate are discussed during renal replacement therapy in critically ill patients with particular focus on the practical approach at the bedside.

引用

页码：115 / 127

页数：13

共 17 条

[1] Apsner R, 1997, WIEN KLIN WOCHENSCHR, V109, P123
[2] Regional citrate anticoagulation in continuous venovenous haemodiafiltration using commercial solutions
Cointault, O
Kamar, N
Bories, P
Lavayssiere, L
Angles, O
Rostaing, L
Genestal, M
Durand, D
[J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2004, 19 (01) : 171 - 178
[3] A novel citrate anticoagulation regimen for continuous venovenous hemodiafiltration
Dorval, M
Madore, F
Courteau, S
Leblanc, M
[J]. INTENSIVE CARE MEDICINE, 2003, 29 (07) : 1186 - 1189
[4] Citrate anticoagulation in continuous venovenous hemodiafiltration:: a metabolic challenge
Gabutti, L
Marone, C
Colucci, G
Duchini, F
Schönholzer, C
[J]. INTENSIVE CARE MEDICINE, 2002, 28 (10) : 1419 - 1425
[5] Current Canadian approaches to dialysis for acute renal failure in the ICU
Hyman, A
Mendelssohn, DC
[J]. AMERICAN JOURNAL OF NEPHROLOGY, 2002, 22 (01) : 29 - 34
[6] Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy: All Citrates Are Not Created Equal!
Jacobs, Rita
Honore, Patrick M.
Hendrickx, Inne
Spapen, Herbert D.
[J]. BLOOD PURIFICATION, 2016, 42 (03) : 219 - 220
[7] Citrate Formulation Determines Filter Lifespan during Continuous Veno-Venous Hemofiltration: A Prospective Cohort Study
Jacobs, Rita
Honore, Patrick M.
Bagshaw, Sean M.
Diltoer, Marc
Spapen, Herbert D.
[J]. BLOOD PURIFICATION, 2015, 40 (03) : 194 - 202
[8] Facing acid-base disorders in the third millennium - the Stewart approach revisited
Kishen, R.
Honore, Patrick M.
Jacobs, R.
Joannes-Boyau, O.
De Waele, E.
De Regt, J.
Van Gorp, V.
Boer, W.
Spapen, H. D.
[J]. INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE, 2014, 7 : 209 - 217
[9] Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients
Kutsogiannis, DJ
Gibney, RTN
Stollery, D
Gao, J
[J]. KIDNEY INTERNATIONAL, 2005, 67 (06) : 2361 - 2367
[10] REGIONAL CITRATE ANTICOAGULATION FOR CONTINUOUS ARTERIOVENOUS HEMODIALYSIS IN CRITICALLY ILL PATIENTS
MEHTA, RL
MCDONALD, BR
AGUILAR, MM
WARD, DM
[J]. KIDNEY INTERNATIONAL, 1990, 38 (05) : 976 - 981

← 1 2 →